- Home
- TWG vs APLM Comparison
TWG vs APLM Comparison
Compare TWG & APLM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TWG
- APLM
- Stock Information
- Founded
- TWG 2009
- APLM 2016
- Country
- TWG Hong Kong
- APLM United States
- Employees
- TWG N/A
- APLM N/A
- Industry
- TWG
- APLM Blank Checks
- Sector
- TWG
- APLM Finance
- Exchange
- TWG NYSE
- APLM Nasdaq
- Market Cap
- TWG 7.7M
- APLM 6.9M
- IPO Year
- TWG 2024
- APLM N/A
- Fundamental
- Price
- TWG $0.11
- APLM $6.50
- Analyst Decision
- TWG
- APLM
- Analyst Count
- TWG 0
- APLM 0
- Target Price
- TWG N/A
- APLM N/A
- AVG Volume (30 Days)
- TWG 4.2M
- APLM 9.7K
- Earning Date
- TWG 02-15-2025
- APLM 04-03-2025
- Dividend Yield
- TWG N/A
- APLM N/A
- EPS Growth
- TWG N/A
- APLM N/A
- EPS
- TWG N/A
- APLM N/A
- Revenue
- TWG $4,747,580.00
- APLM $198,000.00
- Revenue This Year
- TWG N/A
- APLM $415.15
- Revenue Next Year
- TWG N/A
- APLM N/A
- P/E Ratio
- TWG N/A
- APLM N/A
- Revenue Growth
- TWG N/A
- APLM N/A
- 52 Week Low
- TWG $0.10
- APLM $4.47
- 52 Week High
- TWG $13.50
- APLM $35.98
- Technical
- Relative Strength Index (RSI)
- TWG N/A
- APLM 53.81
- Support Level
- TWG N/A
- APLM $5.96
- Resistance Level
- TWG N/A
- APLM $7.39
- Average True Range (ATR)
- TWG 0.00
- APLM 0.77
- MACD
- TWG 0.00
- APLM 0.08
- Stochastic Oscillator
- TWG 0.00
- APLM 54.43
About TWG TOP WEALTH GROUP HLDG LTD
Top Wealth Group Holding Ltd is as supplier of caviar and offer caviar-based gourmet products. It is specialized in supplying high quality sturgeons caviar.
About APLM Apollomics Inc.
Apollomics Inc is an clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company programs include vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia.